achondroplasia
Rare disease · 2022–2022
2decisions
1medicine
2carried consumer input
198individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| vosoritide Treatment of patients with achondroplasia whose epiphyses are not closed. Vosoritide is indicated to increase linear growth in children with achondroplasia. | Jul 2022 | Not recommended | 99 individuals |
| vosoritide Treatment of patients with achondroplasia whose epiphyses are not closed. | Nov 2022 | Not recommended | 99 individuals |
What the PBS pays
$29M in government benefit over 2024–25, across 1,054 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| vosoritide | $29.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.